Polycystic Ovary Syndrome Market by Roots Analysis

Polycystic ovary syndrome affects 1 in 10 women of childbearing age. The exact cause of the condition is unknown; however, obesity, high levels of inflammation and insulin resistance are the common risk factors

London

Roots Analysis has announced the addition of “Polycystic Ovary Syndrome Market, 2021-2031” report to its list of offerings.

Currently, there is no cure for polycystic ovary syndrome (PCOS / PCOD), however the affiliated symptoms can be treated using a combination of different types of medications, including insulin-sensitizing agents, oral contraceptives, anti-androgens and anti-obesity drugs. The research activities, including clinical investigations in this domain are being driven by both industry and non-industry players.

To order this 90+ page report, which features 70+ figures, please visit https://www.rootsanalysis.com/reports/polycystic-ovarian-syndrome-market.html

Key Market Insights

Currently, more than 60 drugs are marketed / under development for PCOS
More than 80% of the drugs in the market are designed for symptomatic treatment of PCOS whilst a few drugs are being evaluated for curing this clinical condition. Among various types of drugs available, hormonal contraceptives and insulin sensitizing agents are used for the first line treatment. Popular hormonal contraceptives include Beyaz®, Clomid®, Diane 35® and Yasmin®.

More than 40 industry and non-industry players are engaged in the development of drugs for PCOS
Majority of the industry players (70%) are very large firms (having more than 500 employees). North America is the current hub, where close to 45% players are based. This is followed by Europe (28%), Asia-Pacific (9%), and Middle East and North Africa (7%).

Leave a Reply

Your email address will not be published. Required fields are marked *